Press Release

Aleafia aligns with CannTrust

TORONTOMay 1, 2018 /CNW/ – Aleafia Health Inc. (TSXV: ALEF; OTC: CAMDF) (“Aleafia“) or (the “Company“), is pleased to announce a formalized relationship with CannTrust Inc. (TSX: TRST) (“CannTrust“), which both companies feel will be of significant mutual benefit. The companies have entered into a strategic genetic supply agreement through which Aleafia will receive various strains of high-quality starter genetics for its first licensed production facility in Scugog, Ontario, and CannTrust taking the right of first refusal to purchase product from Aleafia.

CannTrust has provided starter genetics to Aleafia for cultivation, which is underway at the Aleafia Farms licensed facility. Aleafia is expecting to complete its first harvest in May and, once completed, Aleafia is expecting to receive its ACMPR sales and distribution license shortly thereafter, subject to a successful inspection by Health Canada.

CannTrust will also have the ability to purchase product from Aleafia’s harvest. This would support CannTrust’s patient base and provide Aleafia with revenue growth in the near term, augmenting the existing revenue derived from the nationwide Canabo clinic network.

Aleafia chose to work with CannTrust because of CannTrust’s demonstrably high-quality production standards and quality genetics. As part of the agreement, Aleafia will also refer a significant percentage of its growing patient base to CannTrust, in cases where patients require strains that Aleafia may not initially be able to supply out of the current facility. Notably, Aleafia has begun an expansion strategy to increase cultivation capacity from its current abilities. The initial-phase expansion of 150,000 square feet is fully funded with plans for future expansion on its 76-acre property in Scugog, Ontario.

“The entire Aleafia team is pleased with this exciting opportunity to work with CannTrust,” said Executive Director Julian Fantino. “Standardized repeatable product for our patients is something we feel strongly about at Aleafia and is a critical part of meeting the exacting standards required by our expanding network of more than 30,000 patients. CannTrust already does this very well, which made the decision to work together an easy one. We thank CannTrust for its continued support and look forward to working closely together in the future.”

“This relationship is strategic for us as the Aleafia model is complementary to ours on many levels,” said CannTrust President Brad Rogers. “Aleafia’s ability to meet our rigorous production-quality standards and deliver high-quality product is key, along with CannTrust being the preferred partner in Aleafia’s clinic business. This relationship is a real win-win for both organizations.”

 

For Investor Relations, please contact:

IR@AleafiaInc.com  

 

For Media Relations, please contact:

Nicholas Bergamini, VP Public Affairs

416-860-5665 ext. 224

Media@AleafiaInc.com

 

About Aleafia Health Inc.:

Aleafia is a leading, vertically integrated medical cannabis company with a unique focus on delivering quality patient care from “seed” to “sale.” Aleafia is uniquely positioned with a singular focus on the medical cannabis market. The company operates the largest brick and mortar medicinal cannabis clinic network in Canada under the Canabo Medical Clinic brand, which is staffed by licensed, practicing physicians. Aleafia has obtained over 50,000 unique patients and maintains the largest medical cannabis patient data set in Canada. Aleafia’s state of the art production facilities will allow for the production of high- quality strains at low cost. Aleafia’s production will focus on securing the highest- quality medicinal product for its growing patient base.

 

Neither Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

FORWARD LOOKING INFORMATION

 

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations.  When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information.  The forward-looking statements and information in this press release includes information relating to the implementation of Aleafia Health’s business plan.  Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, among others, the following risks: risks associated with the implementation of Aleafia Health’s business plan and matters relating thereto, risks associated with the cannabis industry, competition, regulatory change, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume.  Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change.  Investors are cautioned against attributing undue certainty to forward-looking statements.